{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T20:57:35Z","timestamp":1783976255052,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Radiol"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Wild-type transthyretin-related amyloidosis cardiomyopathy (ATTRwt-CM) is an increasingly recognized cause of heart failure especially in elderly patients. The purpose of the present study was to determine retrospectively whether the quantitative indices of <jats:sup>99m<\/jats:sup>Tc-pyrophosphate (PYP) SPECT\/CT help to predict the prognosis of ATTRwt-CM patients when compared with other clinical parameters.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>Sixty-eight patients with biopsy-proven ATTRwt-CM who underwent PYP SPECT\/CT were enrolled. Baseline clinical characteristics, echocardiographic parameters, and qualitative and\/or quantitative indices of planar and SPECT\/CT imaging in PYP scintigraphy for each patient were included. For quantitative analysis of SPECT\/CT, the accumulation ratio of PYP in the septum, posterior, anterior, lateral, and apex walls to the cavity pool was calculated as the septal wall-to-cavity ratio (Se\/C), lateral wall-to-cavity ratio (La\/C), anterior wall-to-cavity ratio (An\/C), inferior wall-to-cavity ratio (In\/C), and apical wall-to-cavity ratio (Ap\/C), respectively. Endpoints for prognostic accuracy evaluation were cardiac death or hospitalization due to heart failure. Event-free survival rate was evaluated through Cox proportional hazards regression analysis, providing estimated hazard ratios (HRs) with 95% confidence intervals (CIs) and Kaplan\u2013Meier curves.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>High-sensitivity cardiac troponin T (hs-cTnT), La\/C, age, interventricular septal thickness in diastole, and <jats:italic>E<\/jats:italic>\/<jats:italic>e<\/jats:italic>\u2032 ratio in the septal wall were significantly associated with event-free survival (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). For a multivariable Cox proportional hazards analysis, hs-cTnT (HR 1.153; 95% CI 1.034\u20131.286;\u00a0<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01), La\/C (HR 2.091; 95% CI 1.012\u20134.322;\u00a0<jats:italic>P<\/jats:italic>\u2009=\u20090.046), and age (HR 1.116; 95% CI 1.007\u20131.238;\u00a0<jats:italic>P<\/jats:italic>\u2009=\u20090.037) were significant independent prognostic factors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study indicated that the quantitative indices of PYP SPECT\/CT can help to predict the prognosis of ATTRwt-CM patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11604-021-01221-6","type":"journal-article","created":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T07:16:29Z","timestamp":1641021389000},"page":"508-517","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Usefulness of quantitative 99mTc-pyrophosphate SPECT\/CT for predicting the prognosis of patients with wild-type transthyretin cardiac amyloidosis"],"prefix":"10.1007","volume":"40","author":[{"given":"Kouji","family":"Ogasawara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumi","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seitarou","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Takashio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Tsujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinori","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,1]]},"reference":[{"key":"1221_CR1","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","volume":"36","author":"E Gonz\u00e1lez-L\u00f3pez","year":"2015","unstructured":"Gonz\u00e1lez-L\u00f3pez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36:2585\u201394.","journal-title":"Eur Heart J"},{"key":"1221_CR2","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1056\/NEJM199702133360703","volume":"336","author":"DR Jacobson","year":"1997","unstructured":"Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med. 1997;336:466\u201373.","journal-title":"N Engl J Med"},{"key":"1221_CR3","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1056\/NEJMra023144","volume":"349","author":"G Merlini","year":"2003","unstructured":"Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349:583\u201396.","journal-title":"N Engl J Med"},{"key":"1221_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/imj.12288","volume":"44","author":"P Mollee","year":"2014","unstructured":"Mollee P, Renaut P, Gottlieb D, Goodman H. How to diagnose amyloidosis. Intern Med J. 2014;44:7\u201317.","journal-title":"Intern Med J"},{"key":"1221_CR5","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133:2404\u201312.","journal-title":"Circulation"},{"key":"1221_CR6","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/0002-8703(87)90703-4","volume":"113","author":"M Hongo","year":"1987","unstructured":"Hongo M, Hirayama J, Fujii T, Yamada H, Okubo S, Kusama S, et al. Early identification of amyloid heart disease by technetium-99m-pyrophosphate scintigraphy: a study with familial amyloid polyneuropathy. Am Heart J. 1987;113:654\u201362.","journal-title":"Am Heart J"},{"key":"1221_CR7","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/0002-8703(82)90331-3","volume":"103","author":"TA Wizenberg","year":"1982","unstructured":"Wizenberg TA, Muz J, Sohn YH, Samlowski W, Weissler AM. Value of positive myocardial technetium-99m-pyrophosphate scintigraphy in the noninvasive diagnosis of cardiac amyloidosis. Am Heart J. 1982;103:468\u201373.","journal-title":"Am Heart J"},{"key":"1221_CR8","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","volume":"46","author":"E Perugini","year":"2005","unstructured":"Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46:1076\u201384.","journal-title":"J Am Coll Cardiol"},{"key":"1221_CR9","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1001\/jamacardio.2016.2839","volume":"1","author":"A Castano","year":"2016","unstructured":"Castano A, Haq M, Narotsky DL, Goldsmith J, Weinberg RL, Morgenstern R, et al. Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol. 2016;1:880\u20139.","journal-title":"JAMA Cardiol"},{"key":"1221_CR10","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1093\/ehjci\/jew325","volume":"18","author":"DF Hutt","year":"2017","unstructured":"Hutt DF, Fontana M, Burniston M, Quigley AM, Petrie A, Ross JC, et al. Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid. Eur Heart J Cardiovasc Imaging. 2017;18:1344\u201350.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"1221_CR11","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jcmg.2017.06.020","volume":"11","author":"BW Sperry","year":"2018","unstructured":"Sperry BW, Vranian MN, Tower-Rader A, Hachamovitch R, Hanna M, Brunken R, et al. Regional variation in technetium pyrophosphate uptake in transthyretin cardiac amyloidosis and impact on mortality. JACC Cardiovasc Imaging. 2018;11:234\u201342.","journal-title":"JACC Cardiovasc Imaging"},{"key":"1221_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s41824-018-0035-1","volume":"2","author":"SC Ramsay","year":"2018","unstructured":"Ramsay SC, Lindsay K, Fong W, Patford S, Younger J, Atherton J. Tc-HDP quantitative SPECT\/CT in transthyretin cardiac amyloid and the development of a reference interval for myocardial uptake in the non-affected population. Eur J Hybrid Imaging. 2018;2:17.","journal-title":"Eur J Hybrid Imaging"},{"key":"1221_CR13","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1253\/circj.CJ-17-1111","volume":"82","author":"N Tsuda","year":"2018","unstructured":"Tsuda N, Shiraishi S, Oda S, Ogasawara K, Sakamoto F, Tomiguchi S, et al. Utility of single-photon emission computed tomography\/computed tomography fusion imaging with (99 m)Tc-pyrophosphate scintigraphy in the assessment of cardiac transthyretin amyloidosis. Circ J. 2018;82:1970\u20131.","journal-title":"Circ J"},{"key":"1221_CR14","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0894-7317(89)80014-8","volume":"2","author":"NB Schiller","year":"1989","unstructured":"Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of echocardiography committee on standards, subcommittee on quantitation of two-dimensional echocardiograms. J Am Soc Echocardiogr. 1989;2:358\u201367.","journal-title":"J Am Soc Echocardiogr"},{"key":"1221_CR15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s12350-016-0610-4","volume":"25","author":"S Bokhari","year":"2018","unstructured":"Bokhari S, Morgenstern R, Weinberg R, Kinkhabwala M, Panagiotou D, Castano A, et al. Standardization of (99m)technetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis. J Nucl Cardiol. 2018;25:181\u201390.","journal-title":"J Nucl Cardiol"},{"key":"1221_CR16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ijcard.2020.02.030","volume":"307","author":"C Grigoratos","year":"2020","unstructured":"Grigoratos C, Aimo A, Rapezzi C, Genovesi D, Barison A, Aquaro GD, et al. Diphosphonate single-photon emission computed tomography in cardiac transthyretin amyloidosis. Int J Cardiol. 2020;307:187\u201392.","journal-title":"Int J Cardiol"},{"key":"1221_CR17","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","volume":"68","author":"M Grogan","year":"2016","unstructured":"Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68:1014\u201320.","journal-title":"J Am Coll Cardiol"},{"key":"1221_CR18","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","volume":"39","author":"JD Gillmore","year":"2018","unstructured":"Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39:2799\u2013806.","journal-title":"Eur Heart J"},{"key":"1221_CR19","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1007\/s00392-019-01559-y","volume":"109","author":"MM Kreusser","year":"2020","unstructured":"Kreusser MM, Volz MJ, Knop B, Ehlermann P, Schmack B, Ruhparwar A, et al. A novel risk score to predict survival in advanced heart failure due to cardiac amyloidosis. Clin Res Cardiol. 2020;109:700\u201313.","journal-title":"Clin Res Cardiol"},{"key":"1221_CR20","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1253\/circrep.CR-20-0031","volume":"2","author":"Y Ochi","year":"2020","unstructured":"Ochi Y, Kubo T, Baba Y, Nakashima Y, Ueda M, Takahashi A, et al. Prediction of medium-term mortality in Japanese patients with wild-type transthyretin amyloidosis. Circ Rep. 2020;2:314\u201321.","journal-title":"Circ Rep"},{"key":"1221_CR21","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1002\/ehf2.12884","volume":"7","author":"T Yamada","year":"2020","unstructured":"Yamada T, Takashio S, Arima Y, Nishi M, Morioka M, Hirakawa K, et al. Clinical characteristics and natural history of wild-type transthyretin amyloid cardiomyopathy in Japan. ESC Heart Fail. 2020;7:2829\u201337.","journal-title":"ESC Heart Fail"},{"key":"1221_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40658-020-00342-7","volume":"8","author":"C Ren","year":"2021","unstructured":"Ren C, Ren J, Tian Z, Du Y, Hao Z, Zhang Z, et al. Assessment of cardiac amyloidosis with (99m)Tc-pyrophosphate (PYP) quantitative SPECT. EJNMMI Phys. 2021;8:3.","journal-title":"EJNMMI Phys"},{"key":"1221_CR23","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/j.jcmg.2020.03.020","volume":"13","author":"PR Scully","year":"2020","unstructured":"Scully PR, Morris E, Patel KP, Treibel TA, Burniston M, Klotz E, et al. DPD quantification in cardiac amyloidosis: a novel imaging biomarker. JACC Cardiovasc Imaging. 2020;13:1353\u201363.","journal-title":"JACC Cardiovasc Imaging"},{"key":"1221_CR24","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2967\/jnmt.118.223297","volume":"47","author":"A Tzortzakakis","year":"2019","unstructured":"Tzortzakakis A, Holstensson M, Hagel E, Karlsson M, Axelsson R. Intra- and interobserver agreement of SUV SPECT Quantitative SPECT\/CT processing software, applied in clinical settings for patients with solid renal tumors. J Nucl Med Technol. 2019;47:258\u201362.","journal-title":"J Nucl Med Technol"}],"container-title":["Japanese Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-021-01221-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11604-021-01221-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-021-01221-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T23:29:55Z","timestamp":1651706995000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11604-021-01221-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["1221"],"URL":"https:\/\/doi.org\/10.1007\/s11604-021-01221-6","relation":{},"ISSN":["1867-1071","1867-108X"],"issn-type":[{"value":"1867-1071","type":"print"},{"value":"1867-108X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,1]]},"assertion":[{"value":"4 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocol of this study was received and approved by our institutional ethical committee. All the procedures performed in these studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}